Author(s): Rhoden E, Zhang M, Nix WA, Oberste MS
Abstract Share this page
Abstract In 2014, the United States experienced a large outbreak of severe respiratory illness associated with enterovirus D68 (EV-D68). We used a homogeneous, cell-based assay to assess the antiviral activity of compounds developed for EV/rhinovirus infection or other indications. Three of 15 compounds were highly active against all four strains tested (the prototype and three 2014 strains), with 50\% effective concentrations of 0.0012 to 0.027 μM. Additional studies are needed to assess their in vivo efficacy against EV-D68. Copyright © 2015, American Society for Microbiology. All Rights Reserved.
This article was published in Antimicrob Agents Chemother
and referenced in Journal of Antivirals & Antiretrovirals